Everolimus Slows Disease Progression In Advanced Papillary Kidney Cancer Patients

The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress (ECC2013) [1]. read more

Read the whole article on

More from